Cormac Sheridan
Odyssey Therapeutics Inc. closed a hefty $168 million series B round to progress multiple small-molecule and protein-based drug discovery and development programs in autoimmune disease and cancer.
The Boston-based company landed with a splash last year, raising $218 million in a series A round and setting out ambitions to unleash next-generation chemistry, structural biology and computational approaches on a broad range of undrugged targets, typically upstream signaling nodes that control pathways considered to be important disease drivers.